Thrombosis Canada and CanVECTOR thank everyone who attended our recent conference. Over 500 individuals registered to attend the program, a record for our annual meeting.
We’re pleased to announce that we have added recordings of several sessions to this page and our YouTube Channel. Click on the recording below to access them:
Thrombosis and COVID-19: Canadian Experts Perspectives
COVID-19 infection may significantly impact the normal coagulation processes in affected individuals. Much has been learned about COVID-19 and its implications over the past few months. This presentation will review specific aspects including coagulopathy, prophylaxis and treatment of thrombosis, and managing patients with thrombosis virtually.
Current Evidence: Antithrombotic Therapy for AF with CAD
Clinicians frequently face a conundrum in the antithrombotic management of patients with atrial fibrillation (AF) and coronary artery disease (CAD). Stroke (and systemic embolism) risk in AF is best mitigated with the use of oral anticoagulation (OAC) instead of antiplatelet therapy. However, patients with an acute coronary syndrome (ACS) or stable CAD and/or undergoing percutaneous coronary intervention (PCI) have traditionally been managed with dual antiplatelet therapy (ASA [aspirin]]+ P2Y12 receptor inhibitor [e.g., clopidogrel]) to reduce the risk for stent thrombosis and coronary ischemic events. The role for triple (ASA + P2Y12 receptor inhibitor + OAC) vs. Dual (single antiplatelet + OAC) therapy in these clinical settings has been examined in several randomized clinical trials. These studies have also evaluated the role of the non-vitamin k antagonists (VKA) OACs (NOACs) vs. VKA (e.g., warfarin). The results from these trials will be discussed in the context of a case-based scenario and the Canadian Cardiovascular Society (CCS) guideline recommendations.
Peripheral Artery Disease in 2020
Patients with symptomatic lower extremity peripheral artery disease (LE-PAD) experience an increased risk of major vascular events. There is limited information on what clinical features of symptomatic LE-PAD prognosticate major vascular events and whether patients at high risk have a greater absolute benefit from low-dose rivaroxaban and aspirin. This presentation outlines the latest data on this important topic.
VTE in Primary Care: What do we need to know?
VTE is a not uncommon occurrence in our patients, and the consequences can be life threatening. With the current use of DOACS, VTE can be safely and effectively managed in most cases in our office. How do we diagnose? How do we treat? How long do we treat for? Dr Jeff Habert presented this during the Thrombosis Canada virtual conference in October
ASA and Primary Prevention
The benefits of acetylsalicylic acid (ASA) for secondary prevention of atherosclerotic cardiovascular disease are well established. In contrast, although low-dose ASA therapy for primary prevention of atherosclerotic cardiovascular disease was once commonly recommended, this practice is now being reconsidered in light of recent evidence. Three large randomized controlled trials on primary prevention found no net benefit of ASA for prevention of cardiovascular events or mortality in healthy older adults. The presentation will review these and other data on this important clinical issue.
Thrombosis Canada’s Thrombophilia Testing Algorithm
There are a number of inherited and acquired conditions associated with an increased risk of developing venous thromboembolism (VTE). Very often, the presence of these conditions – commonly known as “thrombophilias” – does not change how patients are treated, nor inform their prognosis. Yet sometimes, it does – and it can impact how we counsel patients, treat their thrombosis, and prevent future clots. When a patient develops a VTE, we should consider the site of the clot, whether there are associated features, and whether it is a first or recurrent. This presentation delivered by Dr Menaka Pai at our virtual conference.
Perioperative Anticoagulant Management: An Update
Determining the best course of action with respect to anticoagulation in the perioperative period is multifactorial. Patients must be assessed on an individual basis. The assessment should consist of whether anticoagulation needs to be interrupted and if so for how long. The length of interruption will depend on which agent the patient is taking and the bleeding risk of the procedure. Other considerations include previous clotting or bleeding history, mobility post procedure etc.. The goal of this presentation will be to discuss all factors affecting decisions on anticoagulation in the perioperative period and review the most recent literature/guidelines surrounding this topic. Patient specific cases will be used to highlight the thought process and review how to construct a patent care plan surrounding anticoagulants in the perioperative period. This presentation from Corry Clarke, Pharmacist was delivered as part of our virtual conference in October 2020
Thrombosis Canada Program Co-chairs:
Lana Castellucci, MD, FRCPC, MSc and Eric Tseng, MD, MScCH, FRCPC
CanVECTOR Program Co-chairs:
Eric Tseng, MD, MScCH, FRCPC and Patricia Liaw, BSc, MSc, PhD
MEETING OBJECTIVES
After completing this program, participants will be equipped to:
- Apply current evidence in the management of patients with thrombotic disease;
- Manage thrombosis challenges in face-to-face and virtual clinical practice effectively;
- Describe thrombosis prophylaxis and treatment in patients affected by COVID-19;
- Implement thrombosis treatment options in a variety of patient populations.
TARGET AUDIENCE
Physicians, nurses and pharmacists involved in the management of patients with challenging medical or surgical conditions requiring personalized anticoagulant management.
Unrestricted support for this program is provided by Alexion Canada, BMS-Pfizer alliance, Bayer Canada, Leo Canada, Pfizer Injectables Canada, Sanofi Canada and Servier Canada.